Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daxas REMS May Be Key To Approval After "Complete Response" Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA seems more likely to approve the COPD if labeling is restricted to moderate-to-severe patients with chronic bronchitis, but Forest will probably need to show that it can limit use.

You may also be interested in...



For Forest, Two Launches And Two Filings Planned In 2011 As Patent Cliff Looms

On the heels of a strong quarter, Forest has launched the antibiotic Teflaro and plans to introduce the oral COPD candidate Daxas, later this year pending FDA approval.

For Forest, Two Launches And Two Filings Planned In 2011 As Patent Cliff Looms

On the heels of a strong quarter, Forest has launched the antibiotic Teflaro and plans to introduce the oral COPD candidate Daxas, later this year pending FDA approval.

Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug

Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel